All In Biotech

NDA 210450 · Abbvie

Orilissa

Elagolix Sodium · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jul 23, 2018

Approved uses

4

Original approval plus efficacy supplements

Registered trials

34

15 Phase 3, 1 recruiting

FAERS reports

3,729

1,319 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 19, 2025.

ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. ( 1 ) Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ). ( 1 )

Mechanism: ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ORILISSA · ELAGOLIX SODIUM EQ 150MG BASE · TABLET, ORAL · Prescription
  • ORILISSA · ELAGOLIX SODIUM EQ 200MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Elagolix" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hot flush471
  • pain437
  • nausea327
  • endometriosis304
  • headache277
  • drug ineffective253
  • depression214
  • arthralgia200
  • anxiety163
  • insomnia151
  • suicidal ideation148
  • adverse drug reaction140

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201849
2019930
20201,090
2021517
2022700
2023223
2024121
202575
202624

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orilissa (Elagolix Sodium)

2024 spending

$3.2M

Beneficiaries

511

2,310 claims

Per beneficiary

$6,174

$36.59 per unit

View as table
YearSpending
2020$2,971,696
2021$3,343,652
2022$3,696,413
2023$3,632,354
2024$3,154,831

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.